Milestone (MIST) Q2 2026 earnings review
Launch Accelerates as Payer Coverage Doubles
Milestone's CARDAMYST launch is gaining serious traction. Second-quarter product revenue more than doubled sequentially to $0.6M, driven by an accelerating surge in prescriptions. The critical unlock was payer access: covered lives jumped from 25% to 50% following a major UnitedHealthcare win, alleviating the 'natural dampening' effect of prior authorizations. SG&A expenses are accelerating ($22.6M) to fund the commercial push, but with $170.6M in cash, the company has stable runway into late 2027 to execute the launch and advance its Phase 3 AFib-RVR trial.
🐂 Bull Case
The jump to 50% commercial coverage via UnitedHealthcare is a massive catalyst. It directly reduces physician friction and drives higher pharmacy pull-through rates, which were previously suppressing script volume.
It took ~6 weeks to hit 300 scripts, another 4 weeks to hit 600, and only 8 weeks to add 900 more. This accelerating curve proves the 60-person sales force is gaining efficiency.
🐻 Bear Case
Despite 1,500 cumulative scripts, Q2 product revenue was only $0.6M. This indicates heavy continued reliance on patient assistance programs (free drug/co-pay bridges) which will compress margins until coverage matures.
SG&A expenses hit $22.6M in the quarter. The cost of acquiring these initial prescriptions is exceptionally high, requiring significant revenue scale to achieve operational profitability.
⚖️ Verdict: 🟢
Bullish. The commercial execution is delivering exactly what is needed at this stage: exponential growth in prescriber breadth and script volume, unlocked by major formulary wins. The cash runway is sufficient to support the high initial burn rate.
Key Themes
The Payer Coverage Tipping Point
Securing UnitedHealthcare and other prominent commercial insurers doubled covered lives from 25% to 50%. Management previously identified payer access as the single most important accelerator for the launch. By removing prior authorization hurdles, this allows the sales force's efforts to translate directly into dispensed prescriptions rather than abandoned pharmacy fills.
Sales Force Yield Accelerating
The 60-person sales force is demonstrating strong leverage. Unique prescribers doubled from 400 in April to over 800 by June 30. More importantly, the ratio of scripts to prescribers is widening (from roughly 1.5:1 to nearly 2:1), signaling that doctors are moving beyond initial trial and prescribing CARDAMYST to multiple patients.
AFib-RVR Pipeline Advancement
The Phase 3 ReVeRA-301 trial in atrial fibrillation with rapid ventricular rate (AFib-RVR) is now open with several sites activated. This is a critical technological innovation leveraging the self-administered nasal delivery platform for a much larger adjacent market (~10 million US patients vs ~2 million for PSVT), transforming Milestone from a single-indication to a franchise story.
Accelerating Commercial Burn
Selling, general and administrative expenses surged to $22.6M in Q2 (up from $15.8M in Q1 and $8.9M a year ago). While expected during a launch, the steep trajectory of these costs means the company must rapidly convert its new payer coverage into gross-to-net revenue improvements to prevent the cash runway from deteriorating faster than projected.
Net Revenue per Script Remains Compressed
While 1,500 total scripts is an impressive milestone, Q2 product revenue was only $0.6M. This clearly contradicts the positive volume narrative by highlighting that free-drug bridging and co-pay assistance programs are still heavily eating into margins. Until Medicare coverage is secured (expected 2027), half the market remains largely unmonetized.
International Timelines Remain Extended
The regulatory macro picture outside the U.S. requires patience. The European Medicines Agency (EMA) decision on etripamil remains slated for H1 2027. Meanwhile, the NDA in China is under review via partner Everest Medicines. Milestone is entirely dependent on U.S. commercial execution for the next 12-18 months.
Other KPIs
Down slightly from $184.2 million at the end of Q1, but up significantly from $106.0 million at year-end 2025. The current burn rate of ~$13.6M for the quarter was heavily insulated by the Q1 royalty payment. This fortress balance sheet allows the company to operate from a position of strength during payer negotiations.
Accelerating sequentially from $0.2M in Q1. While absolute numbers remain small, the 150% QoQ growth rate aligns with the physical expansion of prescription volume.
Guidance
Stable. Management reiterated that the current $170.6M balance is sufficient to cover operating and capital expenditures into the second half of 2027, fully funding the initial CARDAMYST launch and the ReVeRA-301 Phase 3 trial initiation.
Stable. The company confirmed that clinical sites are now activated and they remain on track to enroll the first AFib-RVR patient in the second half of the year.
Stable. The marketing authorization application for etripamil for PSVT in Europe remains on track for an H1 2027 decision.
Key Questions
Medicare Coverage Timeline
With commercial coverage now at 50%, what is the latest outlook and strategic plan for securing Medicare coverage, which represents roughly half of the total PSVT patient population?
Gross-to-Net Realization
How quickly do you expect the new UnitedHealthcare formulary placement to translate into improved net revenue per script? Are you seeing a reduction in the reliance on patient assistance programs?
SG&A Trajectory
SG&A expense increased to $22.6 million this quarter. Has commercial spending reached its peak run-rate for the current 60-person sales force, or should we expect continued escalation in the second half of 2026?
Refill Rates and Patient Adherence
Of the >1,300 patients who have filled scripts, what percentage are requesting refills? Can you share any early data on utilization frequency per patient?